Options IX Abstract Policies


Late Breaking Abstracts: 

Please note that this opportunity is not for abstracts that missed the deadline. Abstracts submitted during this late-breaking time, 1 June 2016 through 22 June 2016, will only be considered if the data and/or analysis were not available before the Options IX regular submission date of April 1, 2016. There are no exceptions. There will be very limited slots for late breaking presentations.  

Abstracts can be submitted into 3 categories: Public Health, Virology and Pathogenesis, and Clinical Science.


  1. Category Submission
    • Abstracts can be submitted into 3 categories: Public Health, Virology and Pathogenesis, and Clinical Science.
  2. Publication
    • Upon submission of an abstract, the author provides consent to allow ISIRV to publish the abstract in the onsite Options IX program book, and posted on the Options IX website 1 month prior to the conference.  
  3. Previous Presentation of Abstracts
    • Abstracts will not be considered for presentation if they will be published as an article within 30 days prior to the start of Options IX, or if they have been previously presented at a national meeting not sponsored by ISIRV. Exception: Abstracts presented or accepted for presentation by a young investigator (defined as a student, resident, or fellow), including those published in a journal supplement associated with ISIRV meeting within the previous year, can be submitted to Options IX.
  4. Informed Consent: 
    • ​​Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966:14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. 
  5. Use of Animals:
    • All studies involving the use of animals must conform to the 1991 revision of "Guiding Principles in the Care and Use of Animals" (American Physiological Association).
  6. Employees of Commercial Interests
    • Options recognizes that employees of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. In order to be compliant with the various continuing medical education regulatory bodies, abstracts submitted by employees of commercial interests should not include patient care recommendations. They should focus on the biology, physiology or physics and include content about the discovery process. Abstracts should avoid discussion of products, treatment or diagnostics. Abstracts from employees of commercial interests that are selected for oral or poster presentation will be subject to additional review prior to Options IX.
  7. Author Disclosure: 
    • ALL abstract authors are required to disclose any conflict of interest.
  8. Co-Author Approval: 
    • Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after April 1, 2016.
  9. Changes to Abstract
    • You are able to edit your abstract until the submission deadline. After the submission deadline, only minor abstract changes (author or institution changes, disclosure, keyword or questionnaire updates) are allowed. The deadline for minor updates and all withdrawals is April 1, 2016.  Any corrections, withdrawals and/or changes will not be accepted after this date.
  10. Abstract Receipt Confirmation 
    • You will receive an email confirmation within two business days of submitting your abstract. If you submit on the deadline date and do not receive a confirmation within two business days, please contact Quadlogic Technical Support.
  11. Notification of Presentation Status
    • ​​Notifications on oral and poster presentation type will be sent no later than April 25, 2016.
  12. Abstract Clinical Content Validation
    • ​​​​​All the recommendations involving clinical medicine in a activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

    • All scientific research referred to, reported, or used in this activity in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    • Abstract content should not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME, or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients. Abstracts containing advocacy of unscientific modalities of diagnosis or therapy will not be considered.

  13. Press Policy

    • In compliance with the Securities and Exchange Commission's Regulation FD (Fair Disclosure), academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract to the conference delegates at the start of the meeting (registration). Information additional to that contained within the abstract, e.g., discussion of the abstract done as part of a scientific presentation, is to be embargoed until the start of the relevant scientific session.

      • Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Journalists failing to abide by the embargo may have their press credentials revoked”.


  1. Abstract Preparation:
    • Abstracts must conform exactly to the instructions provided for electronic submission (by Options IX). Abstracts must be submitted in English and all presentations will be in English.
  2. Layout Submission: 
    • Each abstract will need to include a title, background, methods, and conclusion.
  3. Character Limit:
    • A complete abstract submission will be a maximum of 2,750 characters.  This includes the background, methods, tables, figures, results, conclusions and spaces.  This does NOT include the title, authors and institutions.
  4. ​​File Attachment:
    • File attachment is only for additional figures or tables with the content character count taken into consideration.  This is not used to upload abstracts by pdf.


  1. Abstract Evaluation/Review:
    • ​​Abstracts will be blinded for peer evaluation/review. Authors should be cautious in using institutional references in the title, background, methods, or conclusions of the abstract. Do not put author names and/or affiliations in the title, background, methods, or conclusions. Abstracts which include reference to authors or institutions in the title, background, methods, or conclusions will not be evaluated/reviewed.


Technical support questions related to online abstract submission, contact Quadlogic Technical Support.

Abstract policy, deadlines, notifications, programming, general Options IX questions, contact Jessica Dougherty, jdougherty@ahredchair.com